Stocks · News reference

Chemed Q2 Adj. EPS $6.06 Beats $5.60 Estimate, Sales $673.251M Beat $665.037M Estimate

Jul 28, 2026, 8:16 PMBenzinga Newsdesk

Chemed (NYSE:CHE) reported quarterly earnings of $6.06 per share which beat the analyst consensus estimate of $5.60 by 8.21 percent. This is a 41.92 percent increase over earnings of $4.27 per share from the same period

Read original source More stocks news

Reference details

Connected markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

CHE

Source: benzinga
Observed: Jul 28, 2026, 8:16 PM
Checked: Jul 28, 2026, 8:16 PM
Cadence: Captured once, then retained as an archive reference
Status: fresh

Keep reading

BenzingaAug 27, 2026, 5:14 PMBenzinga Newsdesk
The Capitol Forum Posts On X "Chemed: Vitas Healthcare Misdiagnosed Dementia Patients and 'Fudged' Evaluation Scores in Order to Admit Them into Hospice; Expert Who Reviewed Internal Documents Says They Warrant Federal Investigation"
https://x.com/Capitol_Forum/status/2093021234103488646
Read original at benzinga
CHE
BenzingaJul 31, 2026, 4:08 PMBenzinga Newsdesk
Oppenheimer Maintains Outperform on Chemed, Raises Price Target to $590
Oppenheimer analyst Michael Wiederhorn maintains Chemed (NYSE:CHE) with a Outperform and raises the price target from $500 to $590.
Read original at benzinga
CHE
BenzingaJul 30, 2026, 5:41 PMBenzinga Newsdesk
RBC Capital Maintains Sector Perform on Chemed, Raises Price Target to $548
Read original at benzinga
CHE
SEC EDGARJul 28, 2026, 8:30 PMSEC EDGAR
8-K filing — CHEMED CORP (CHE)
Filed: 2026-07-28 AccNo: 0000019584-26-000018 Size: 2 MB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits
Read original at edgar
CHE

Chemed Q2 Adj. EPS $6.06 Beats $5.60 Estimate, Sales $673.251M Beat $665.037M Estimate

Connected markets

Related headlines

The Capitol Forum Posts On X "Chemed: Vitas Healthcare Misdiagnosed Dementia Patients and 'Fudged' Evaluation Scores in Order to Admit Them into Hospice; Expert Who Reviewed Internal Documents Says They Warrant Federal Investigation"

Oppenheimer Maintains Outperform on Chemed, Raises Price Target to $590

RBC Capital Maintains Sector Perform on Chemed, Raises Price Target to $548

8-K filing — CHEMED CORP (CHE)